Novo Nordisk acquires collaborative partner for USD 1.8bn

Novo Nordisk and Emisphere Technologies have agreed on the terms of a deal which will place the US firm under Danish care for the sum of USD 1.8bn.

Photo: Jacob Gronholt-Pedersen/REUTERS / X04292

A 13-year-old collaboration between Novo Nordisk and Emisphere Technologies now culminates in the acquisition of the latter by the former.

On Friday morning, Novo Nordisk announced that a final deal had been struck to take over the years-long collaborative partner, whose main asset is a technology which aids the formulation of drugs for oral ingestion – a delivery agent called Snac – which Novo Nordisk has employed in, for example, the development of semaglutide in tablet form, that is, the diabetes tablet Rybelsus.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs